cell-mediated cytotoxicity


Also found in: Dictionary, Thesaurus.

cytotoxicity

 [si″to-tok-sis´ĭ-te]
1. the degree to which an agent has specific destructive action on certain cells.
2. the possession of such destructive action, particularly in reference to lysis of cells by immune phenomena and to antineoplastic agents that selectively kill dividing cells. adj., adj cytotox´ic.
antibody-dependent cell-mediated cytotoxicity (ADCC) (antibody-dependent cellular cytotoxicity) lysis of target cells coated with antibody by effector cells with cytolytic activity and specific immunoglobulin receptors called Fc receptors, including K cells, macrophages, and granulocytes. Lysis of the target cell is extracellular, requires direct cell-to-cell contact, and does not involve complement.
cell-mediated cytotoxicity destruction of a target cell by specific lymphocytes, such as cytotoxic T lymphocytes or NK cells; it may be antibody-dependent (see antibody-dependent cell-mediated c.) or independent, as in certain cell-mediated hypersensitivity reactions.

cell-mediated cytotoxicity

cytolysis of a target cell by effector lymphocytes, such as cytotoxic T lymphocytes or natural killer cells. It may be antibody-dependent (antibody-dependent cell-mediated cytotoxicity) or independent, as in certain type IV hypersensitivity reactions.
References in periodicals archive ?
Glycoengineered alemtuzumab, made in CHO cells transfected with glycosyltransferases to change glycosylation to being more comparable to that of production in rat cells, showed higher antibody-dependent cell-mediated cytotoxicity compared to the wild type drug.
dependent cell-mediated cytotoxicity (ADCC), the process by which natural killer cells are activated to target eosinophils.
By retaining a native Fc-region, avelumab is thought to engage the innate immune system and induce antibody-dependent cell-mediated cytotoxicity (ADCC).
Antibody technologies: Chimeric, fully human, humanized, pegylation, Fab fragment, Fc engineering, glycoengineering, antibody drug conjugate (ADC), bispecific antibody, naked antibody, pretargeted radioimmmunotherapy (PT-RAIT), cell-killing agents, cytotoxic agent, toxin, tumor-targeted superantigens (TTS), antibody-dependent cell-mediated cytotoxicity (ADCC) enhancing, complement-dependent cytotoxicity (CDC) enhancing, inhibiting and activating Fc receptors, defucosylation, isotype chimerism, production systems, glycosidase inhibitors, sugar engineering, Fab arm switching or Fab crossover, trifunctional, bispecific T cell engager (BiTE), dual-variable-domain immunoglobulin (DVD-Ig), TandAb, dock and lock (DNL) technology, dual-affinity re-targeting (DART).
Using Xencor's XmAb Fc enhancement technology, MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumour cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
It has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
It has been designed to have significantly improved antibody-dependent cell-mediated cytotoxicity (ADCC), therefore enhancing a central mechanism for tumour cell killing and potentially providing increased efficacy than traditional anti-cancer antibodies.
Of particular note, it has been found to have potent antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and apoptotic activity (achievement of programmed cell death).
TG20 has enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), a key feature useful in the treatment of cancer and auto-immune diseases, and it has been shown to have 10-fold enhanced ADCC when compared side by side with rituximab in assays performed with B-cell chronic lymphocytic leukemia, or B-CLL, patient cancer cell isolates.
It has been designed to have significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) to improve a key mechanism for tumour cell killing and offer potential for better efficacy versus traditional antibodies for cancer treatment.
Using Xencor's XmAb Fc enhancement technology, MOR208 has been engineered to possess enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), which is said to improve a key mechanism for tumor cell killing and offering potential for enhanced efficacy when compared to traditional antibodies for the treatment of cancer.